Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
The Obesity Revolution
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Politics
STAT+

The new Congress is already threatening to push forward on drug pricing, but BIO CEO Jim Greenwood isn’t changing tack

  • Nicholas Florko

By Nicholas Florko Dec. 3, 2018

Reprints
The US Capitol
The U.S. Capitol in Washington, D.C. MANDEL NGAN/AFP/Getty Images

WASHINGTON — BIO CEO Jim Greenwood won’t admit last month’s midterm elections spell trouble for the drug industry.

Despite Democrats taking control of the House of Representatives, floating splashy legislation and openly threatening to investigate drug companies, Greenwood says that come January, he’s going to march into Democrat’s offices and unapologetically sing the praises of the drug industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Nicholas Florko

Nicholas Florko

Reporter, Commercial Determinants of Health

Nicholas Florko reports on the commercial determinants of health.

Tags

There is no epidemic of autism. It’s an epidemic…
There is no epidemic of autism. It’s an epidemic of need
‘I’m terrified’: Patients scramble for treatment after 13 ketamine…
‘I’m terrified’: Patients scramble for treatment after 13 ketamine clinics shut down
Why you get paid to donate plasma but not…
Why you get paid to donate plasma but not blood
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: EU delays pharma legislation again; India cancels license…
Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to…
The surprising biomedical legacy of the Iraq War
The surprising biomedical legacy of the Iraq War

Recommended Stories